Literature DB >> 17952702

Persistent disease in patients with papillary thyroid carcinoma and lymph node metastases after surgery and iodine-131 ablation.

Frederik A Verburg1, Bart de Keizer, Marnix G E H Lam, J M H de Klerk, Cornelis J M Lips, Inne H M Borel-Rinkes, Johannes W van Isselt.   

Abstract

AIM: The aim of this study was to assess the efficacy of treatment of patients with papillary thyroid carcinoma (PTC) and lymph node metastases at the time of diagnosis and its influence on the course of the disease.
METHODS: It is a retrospective review of all 51 patients with PTC and histologically proven lymph node metastases treated with I-131 ablation in our center between January 1990 and January 2003. Patients were considered disease-free if during follow-up thyroglobulin levels were undetectable and scintigraphy with 370 MBq (131)I was negative during thyroid-stimulating hormone stimulation. Staging of patients was in accordance with the 5th edition of the TNM system.
RESULTS: After a median follow-up of 84 months, 33 (65%) patients were never free of detectable disease; and 3 of these patients had died of the PTC. In total, 22 patients still showed persistent activity in the neck outside the thyroid bed, which was suspect to be cervical lymph node metastasis on postablation scintigraphy; it was not related to the initial clinical presentation (lymph node metastasis or a thyroid nodule without suspicion of metastatic disease) or to the extent of surgery. Altogether, 34 patients required additional treatment. Patients presenting with clinically overt lymph node metastasis showed a significantly (p = 0.022) lower rate of becoming disease-free than those in whom microscopic lymph node involvement was unexpectedly found upon pathologic examination. There was no significant association of the eventual outcome with the extent of surgical treatment, TNM staging, or age.
CONCLUSIONS: Patients with lymph node metastasis are considerably less likely to become disease-free. If the initial treatment does not result in a disease-free status, chances are low that additional treatment will succeed in achieving it.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17952702     DOI: 10.1007/s00268-007-9257-2

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  27 in total

1.  Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma.

Authors:  Richard T Kloos; Vani Duvuuri; Sissy M Jhiang; Kenneth V Cahill; Jill A Foster; John A Burns
Journal:  J Clin Endocrinol Metab       Date:  2002-12       Impact factor: 5.958

Review 2.  Papillary and follicular thyroid carcinoma.

Authors:  M J Schlumberger
Journal:  N Engl J Med       Date:  1998-01-29       Impact factor: 91.245

3.  Efficacy of high therapeutic doses of iodine-131 in patients with differentiated thyroid cancer and detectable serum thyroglobulin.

Authors:  B de Keizer; H P Koppeschaar; P M Zelissen; C J Lips; P P van Rijk; A van Dijk; J M de Klerk
Journal:  Eur J Nucl Med       Date:  2001-02

4.  Prognostic significance of successful ablation with radioiodine of differentiated thyroid cancer patients.

Authors:  Frederik A Verburg; Bart de Keizer; Cornelis J M Lips; Pierre M J Zelissen; John M H de Klerk
Journal:  Eur J Endocrinol       Date:  2005-01       Impact factor: 6.664

5.  Fixed dosage of 131I for remnant ablation in patients with differentiated thyroid carcinoma without pre-ablative diagnostic 131I scintigraphy.

Authors:  J M de Klerk; B de Keizer; P M Zelissen; C M Lips; H P Koppeschaar
Journal:  Nucl Med Commun       Date:  2000-06       Impact factor: 1.690

6.  The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.

Authors:  R W Tsang; J D Brierley; W J Simpson; T Panzarella; M K Gospodarowicz; S B Sutcliffe
Journal:  Cancer       Date:  1998-01-15       Impact factor: 6.860

7.  Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis.

Authors:  Sophie Leboulleux; Carole Rubino; Eric Baudin; Bernard Caillou; Dana M Hartl; Jean-Michel Bidart; Jean-Paul Travagli; Martin Schlumberger
Journal:  J Clin Endocrinol Metab       Date:  2005-07-19       Impact factor: 5.958

8.  Radio-guided surgery for lymph node recurrences of differentiated thyroid cancer.

Authors:  Massimo Salvatori; Vittoria Rufini; Francesca Reale; Ana Maria Samanes Gajate; Maria Lodovica Maussier; Luca Revelli; Luigi Troncone; Guglielmo Ardito
Journal:  World J Surg       Date:  2003-07       Impact factor: 3.352

9.  Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.

Authors:  E L Mazzaferri; S M Jhiang
Journal:  Am J Med       Date:  1994-11       Impact factor: 4.965

10.  Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine.

Authors:  F Pacini; F Cetani; P Miccoli; F Mancusi; C Ceccarelli; F Lippi; E Martino; A Pinchera
Journal:  World J Surg       Date:  1994 Jul-Aug       Impact factor: 3.352

View more
  1 in total

Review 1.  Persistent Elevation of Thyroglobulin in Patient Treated for Differentiated Thyroid Cancer: A Ten-Year Review.

Authors:  Sarah Khan; Roopashree Prabhushankar; Emily Leary; Uzma Z Khan
Journal:  Mo Med       Date:  2017 Sep-Oct
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.